Novartis AG ADR (NVS)vsZEN Graphene Solutions Ltd (ZTEK)
NVS
Novartis AG ADR
$145.46
+1.32%
HEALTHCARE · Cap: $271.25B
ZTEK
ZEN Graphene Solutions Ltd
$0.49
0.00%
HEALTHCARE · Cap: $62.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 52372185% more annual revenue ($56.69B vs $108,250). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
ZTEK
Avoid15
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$145.46
$52.06 premium
Margin of Safety
-21.2%
Fair Value
$0.54
Current Price
$0.49
$0.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : ZTEK
The strongest argument for ZTEK centers on Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : ZTEK
The primary concerns for ZTEK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 15/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →ZEN Graphene Solutions Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ZEN Graphene Solutions Ltd (ZTEK) is an innovative leader in the materials technology sector, specializing in the extraction and commercialization of high-purity graphene derived from natural graphite. Through its proprietary techniques, ZTEK is poised to impact numerous industries, including energy storage, environmental remediation, and advanced manufacturing, offering cutting-edge graphene solutions. The company’s strategic focus on sustainability, underpinned by significant research and development initiatives, enhances its competitive edge in the rapidly expanding graphene market. As ZTEK leverages emerging opportunities and continues to advance its technological capabilities, it is well-positioned to deliver substantial long-term value for investors in the context of rising global demand for innovative and advanced materials.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?